Doctors often monitor tumor markers in the blood to help diagnose and treat liver cancer. Alpha-fetoprotein (AFP) is the most common tumor marker that doctors monitor. Tumor markers, also called ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a ...
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, presented results from the Phase 1b dose escalation of the TheraPb Phase 1/2 clinical ...
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) ...
TORONTO--(BUSINESS WIRE)--Alpha Cancer Technologies Inc. (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on ...
MIAMI (AFP) - Cancer is often caused by the "bad luck" of random mutations that arise when cells divide, not family history or environmental causes, US researchers said Thursday. The study in the Jan ...
PARIS, France (AFP) — Cancer will kill nearly 10 million people this year experts said last Wednesday, warning the disease’s global burden continues to rise in spite of better prevention and earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback